Cantargia (CANTA) H.C. Wainwright 28th Annual Global Investment Conference summary

Strategic focus and scientific rationale

• IL1RAP is targeted as a versatile co-receptor involved in tumor immune suppression, chemotherapy resistance, and key inflammatory and oncogenic pathways, impacting oncology and inflammation.

• Blocking IL1RAP aims to selectively target malignant cells, sparing healthy hematopoietic stem cells and reducing off-target effects.

• The CANxx platform generates anti-IL1RAP antibodies, enabling both oncology and autoimmune programs, with CAN10 and CAN14 as lead assets.

• The approach balances efficacy and patient safety by avoiding overly narrow or broad targeting.

• Executive team brings experience from major pharma and biotech firms, supporting robust R&D and commercialization.

Pipeline and clinical development

• Lead antibody nadunolimab is being advanced in PDAC and higher-risk MDS/AML, with bispecific and ADC programs in preclinical development.

• Phase 1b/2a trial at MD Anderson in high-risk MDS/AML showed 5/5 complete remissions in MDS cohort, with favorable safety profile; updated data to be presented at ASH.

• Phase 2a is ongoing, with interim data to be presented at ASH 2026 and completion expected mid-2027.

• In PDAC, nadunolimab plus chemotherapy achieved 13.2 months median OS, outperforming historical controls.

• A phase 1b combination study with daraxonrasib in PDAC will begin after Christmas, enrolling about 15 patients to assess safety and preliminary efficacy.

Clinical results and competitive positioning

• High IL1RAP expression correlates with poor prognosis, but nadunolimab treatment reversed this trend, with high IL1RAP patients achieving 14.2 months median survival.

• Nadunolimab acts via a parallel pathway to RAS/MEK inhibitors and uniquely engages the tumor microenvironment through ADCC.

• Second-line PDAC therapy landscape shifted with daraxonrasib approval, creating new combination opportunities.

• Phase 1b of nadunolimab with daraxonrasib in 2L PDAC to start Q1 2027, focusing on safety and early efficacy.

• Nadunolimab targets IL1RAP on leukemic stem cells, addressing relapse in MDS/AML.